Guido Rasi

List of Publications by Year
in descending order

93 papers	3,836 citations	81900 39 h-index	128289 60 g-index
96 all docs	96 docs citations	96 times ranked	4536 citing authors

#	Article	IF	Citations
1	Thymosin Î± 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood, 2004, 103, 4232-4239.	1.4	189
2	Nanopore Technology for Biomedical Applications. Biomedical Microdevices, 1999, 2, 11-40.	2.8	172
3	Thymosin Î±1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 2006, 108, 2265-2274.	1.4	172
4	From adaptive licensing to adaptive pathways: Delivering a flexible lifeâ€span approach to bring new drugs to patients. Clinical Pharmacology and Therapeutics, 2015, 97, 234-246.	4.7	160
5	The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Experimental Cell Research, 2009, 315, 849-862.	2.6	125
6	Drug Policy for an Aging Population â€" The European Medicines Agency's Geriatric Medicines Strategy. New England Journal of Medicine, 2012, 367, 1972-1974.	27.0	111
7	Nerve Growth Factor: Neurotrophin or Cytokine?. International Archives of Allergy and Immunology, 2003, 131, 80-84.	2.1	104
8	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value in Health, 2017, 20, 487-495.	0.3	101
9	Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 38-46.	5.7	97
10	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clinical Pharmacology and Therapeutics, 2021, 109, 1212-1218.	4.7	97
11	Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 681-692.	5.7	96
12	Open Clinical Trial Data for All? A View from Regulators. PLoS Medicine, 2012, 9, e1001202.	8.4	92
13	AQUAÂ©: Allergy Questionnaire for Athletes. Development and Validation. Medicine and Science in Sports and Exercise, 2009, 41, 1034-1041.	0.4	88
14	Thymosin Â1: An Endogenous Regulator of Inflammation, Immunity, and Tolerance. Annals of the New York Academy of Sciences, 2007, 1112, 326-338.	3.8	87
15	Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response. BMC Immunology, 2008, 9, 17.	2.2	87
16	The risks of risk aversion in drug regulation. Nature Reviews Drug Discovery, 2013, 12, 907-916.	46.4	87
17	Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts. Biomedical Microdevices, 1999, 1, 131-138.	2.8	85
18	Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?. Clinical Pharmacology and Therapeutics, 2019, 105, 912-922.	4.7	76

#	Article	IF	Citations
19	Transparency and the European Medicines Agency â€" Sharing of Clinical Trial Data. New England Journal of Medicine, 2014, 371, 2452-2455.	27.0	69
20	Asthma, allergy and the Olympics. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 184-192.	2.3	66
21	PACAP and VIP prevent apoptosis in schwannoma cells. Brain Research, 2008, 1241, 29-35.	2.2	64
22	Access to Patient-Level Trial Data â€" A Boon to Drug Developers. New England Journal of Medicine, 2013, 369, 1577-1579.	27.0	62
23	Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: Evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/Î²-catenin signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1004-1018.	3.8	61
24	Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Annals of Oncology, 2010, 21, 2081-2087.	1.2	57
25	How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatoryâ€HTA parallel scientific advice. British Journal of Clinical Pharmacology, 2016, 82, 965-973.	2.4	57
26	WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget, 2014, 5, 978-992.	1.8	54
27	Thymosin Â1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. International Immunology, 2007, 19, 1261-1270.	4.0	49
28	Combination therapy with thymosin Î±1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice. International Journal of Cancer, 1992, 50, 493-499.	5.1	48
29	Combination low-dose lymphoblastoid interferon and thymosin Î±1therapy in the treatment of chronic hepatitis B. Journal of Viral Hepatitis, 1996, 3, 191-196.	2.0	48
30	Differentiation of human melanoma cells induced by cyanidinâ€3â€•O â€Î²â€glucopyranoside. FASEB Journal, 2004, 18, 1940-1942.	0.5	48
31	Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clinical Pharmacology and Therapeutics, 2020, 107, 773-779.	4.7	48
32	TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Experimental Cell Research, 2011, 317, 2479-2489.	2.6	45
33	Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.. Gut, 1996, 39, 679-683.	12.1	44
34	Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology, 2000, 22, 1067-1076.	1.1	44
35	Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1166-1170.	5.7	44
36	Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nature Reviews Drug Discovery, 2014, 13, 395-397.	46.4	42

#	Article	IF	Citations
37	Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. International Journal of Cancer, 1994, 57, 701-705.	5.1	41
38	Nerve growth factor and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 13-15.	5.7	41
39	Thymosin Alpha 1. Annals of the New York Academy of Sciences, 2007, 1112, 225-234.	3.8	41
40	Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-Î±l and interferon-Î±2a. European Journal of Cancer, 1995, 31, 2403-2405.	2.8	40
41	Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union. Clinical Cancer Research, 2014, 20, 1458-1468.	7.0	40
42	Drug Regulation and Pricing â€" Can Regulators Influence Affordability?. New England Journal of Medicine, 2016, 374, 1807-1809.	27.0	39
43	Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World Journal of Gastroenterology, 2007, 13, 4986.	3.3	38
44	Thymosin Î±1 in combination with cytokines and chemotherapy for the treatment of cancer. International Immunopharmacology, 2003, 3, 1145-1150.	3.8	37
45	Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma. JAMA Ophthalmology, 2003, 121, 615.	2.4	37
46	The impact of parallel regulatoryâ€"health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. British Journal of Clinical Pharmacology, 2018, 84, 1013-1019.	2.4	34
47	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nature Reviews Drug Discovery, 2016, 15, 516-516.	46.4	32
48	Biochemotherapy with thymosin Î±1, interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects. Annals of Oncology, 1994, 5, 741-746.	1.2	31
49	Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. International Immunopharmacology, 2003, 3, 1169-1176.	3.8	28
50	Combined treatment with thymosin-Î±1 and low dose interferon-Î± after dacarbazine in advanced melanoma. Melanoma Research, 2000, 10, 189-192.	1.2	25
51	Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 33-36.	5.7	24
52	Clinical Trials for COVIDâ€19: Can we Better Use the Short Window of Opportunity?. Clinical Pharmacology and Therapeutics, 2020, 108, 730-733.	4.7	22
53	Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: Transgene expression, immunity and safety. Vaccine, 2006, 24, 4586-4591.	3.8	21
54	Pharmacovigilance 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 89-91.	4.7	20

#	Article	IF	Citations
55	Efficacy of repeated cycles of chemo-immunotherapy with Thymosin Î±1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunology, Immunotherapy, 1999, 48, 172-178.	4.2	19
56	Transcription profile of human lymphocytes following in vitro treatment with thymosin alphaâ€1. Annals of the New York Academy of Sciences, 2010, 1194, 6-19.	3.8	17
57	Fifty years after thalidomide; what role for drug regulators?. British Journal of Clinical Pharmacology, 2012, 74, 731-733.	2.4	17
58	Immunopharmacology of Thymosin Î±1 and Cytokine Synergy. Annals of the New York Academy of Sciences, 2007, 1112, 235-244.	3.8	16
59	Big Data â€“ How to Realize the Promise. Clinical Pharmacology and Therapeutics, 2020, 107, 753-761.	4.7	15
60	Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects. Annals of Oncology, 1995, 6, 1011-1017.	1.2	14
61	First-in-Human Clinical Trials â€" What We Can Learn from Tragic Failures. New England Journal of Medicine, 2016, 375, 1788-1789.	27.0	14
62	Need for Redesigning Pharmacologic Research in Older Individuals. A Position Statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 66-67.	3.6	12
63	Added therapeutic benefit and drug licensing. Nature Reviews Drug Discovery, 2019, 18, 651-652.	46.4	12
64	Differential Expression of a New Tumor-Associated Antigen, TLP, During Human Colorectal Cancer Tumorigenesis. American Journal of Pathology, 1999, 154, 993-999.	3.8	11
65	Steps forward in regulatory pathways for acute and chronic heart failure. European Journal of Heart Failure, 2015, 17, 3-8.	7.1	11
66	<title>Implantation of microfabricated immunoisolating biocapsules</title>. , 1998, 3258, 40.		10
67	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care, 2021, 37, e83.	0.5	10
68	Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model. Journal of Experimental and Clinical Cancer Research, 2012, 31, 9.	8.6	9
69	What we should learn from the London Olympics. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 1-3.	2.3	9
70	Atopic and Vernal Keratoconjunctivitis: A Model for Studying Atopic Disease. , 1999, 28, 88-94.		8
71	A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. , 2000, 85, 540-544.		8
72	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. Pathogens, 2021, 10, 1639.	2.8	7

#	Article	IF	Citations
73	Combination therapy with BRMs in cancer and infectious diseases. Mechanisms of Ageing and Development, 1997, 96, 103-116.	4.6	6
74	Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats. International Journal of Cancer, 2004, 110, 70-75.	5.1	6
75	Innovative medicines: new regulatory procedures for the third millennium. Expert Opinion on Biological Therapy, 2015, 15, 5-8.	3.1	6
76	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. The Histochemical Journal, 1999, 31, 729-737.	0.6	4
77	Detection of high levels of <scp>S</scp>urvivinâ€"immunoglobulin <scp>M</scp> immune complex in sera from hepatitis <scp>C</scp> virus infected patients with cirrhosis. Hepatology Research, 2014, 44, 1008-1018.	3.4	4
78	Steps forward in regulatory pathways for acute and chronic heart failure. ESC Heart Failure, 2014, 1, 87-93.	3.1	4
79	Clinical trial publications: A sufficient basis for healthcare decisions?. European Journal of Internal Medicine, 2020, 71, 13-14.	2.2	4
80	Rationale for Therapeutic Approaches with Thymosin Î± 1, Interleukin 2 and Interferon in Combination with Chemotherapy. , 1992, , 275-281.		4
81	45 Atopy in twins. Journal of Allergy and Clinical Immunology, 1983, 71, 100.	2.9	3
82	The COVIDâ€19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics. Clinical and Translational Science, 2021, 14, 777-780.	3.1	2
83	A critical evaluation of the process of drug discovery and evaluation: is the current approach the best possible one?. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 1.	0.4	2
84	Nerve Growth Factor Regulates the Production of Lung Mucins in a Transgenic Mice Model of Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S250.	2.9	1
85	survivin-IgM immuno complex: A novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A13.	0.9	1
86	European regulatory experience with drugs for central nervous system disorders. Nature Reviews Drug Discovery, 2015, 14, 89-90.	46.4	1
87	Increasing the impact of Post Authorisation Safety Studies: transparency is key. European Journal of Internal Medicine, 2021, 83, 6-7.	2.2	1
88	524 POSTER Stimulatory effect of eucalyptus essential oil on macrophage/graulocyte phagocytic activity: in vitro and in vivo evidences. European Journal of Cancer, Supplement, 2006, 4, 159.	2.2	0
89	Lifestyle, Sports Activities and Allergic Diseases. Journal of Allergy and Clinical Immunology, 2006, 117, S294.	2.9	0
90	Epidemiological Study on Allergy and Asthma Phenotypes: Sub-clinical and Severe Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S1.	2.9	0

#	Article	IF	Citations
91	A cinque anni dal Decreto sugli studi â€œnon profitâ€, come eravamo e dove siamo. Italian Journal of Medicine, 2010, 4, 5-7.	0.3	0
92	PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA. Value in Health, 2011, 14, A172.	0.3	0
93	Legends of allergy and immunology: Sergio Bonini. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3227-3229.	5.7	0